|Dr. Carl Alan Jason Morton Firth||CEO & Exec. Director||N/A||N/A||1973|
|Mr. Kiran Kumar Asarpota||Chief Operating Officer||N/A||N/A||1979|
|Mr. Ben Goodger||Gen. Counsel||N/A||N/A||1963|
|Charlie Hsu||Investor Relations Director||N/A||N/A||N/A|
|Chi-Chin Wang||IR & Corp. Devel. Director||N/A||N/A||N/A|
|Ms. Alison Ward||Chief Devel. Officer||N/A||N/A||N/A|
|Mr. Stephen Doyle||Chief Bus. Officer||N/A||N/A||1973|
|Dr. Kenneth Kobayashi||Chief Medical Officer||N/A||N/A||N/A|
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.